244 related articles for article (PubMed ID: 32733900)
1. Comparison of the Effects of Cyclophosphamide and Mycophenolate Mofetil Treatment Against Immunoglobulin G4-Related Disease: A Retrospective Cohort Study.
Luo X; Peng Y; Zhang P; Li J; Liu Z; Lu H; Zhang X; Zeng X; Zhang F; Fei Y; Zhang W
Front Med (Lausanne); 2020; 7():253. PubMed ID: 32733900
[No Abstract] [Full Text] [Related]
2. Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study.
Chen Y; Li R; Luo X; Wu T; Li J; Liu Z; Peng Y; Lu H; Peng L; Zhou J; Zhao Y; Zeng X; Fei Y; Zhang W
Clin Rheumatol; 2023 Jul; 42(7):1839-1846. PubMed ID: 36781683
[TBL] [Abstract][Full Text] [Related]
3. Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial.
Wang Y; Zhao Z; Gao D; Wang H; Liao S; Dong C; Luo G; Ji X; Li Y; Wang X; Zhao Y; Li K; Zhang J; Jin J; Zhang Y; Zhu J; Zhang J; Huang F
Semin Arthritis Rheum; 2020 Dec; 50(6):1513-1520. PubMed ID: 32113839
[TBL] [Abstract][Full Text] [Related]
4. Addition of second-line steroid sparing immunosuppressants like mycophenolate mofetil improves outcome of Immunoglobulin G4-related disease (IgG4-RD): a series from a tertiary care teaching hospital in South India.
Gupta N; Mathew J; Mohan H; Chowdhury SD; Kurien RT; Christopher DJ; Thangakunam B; Alexander M; Sivadasan A; Tamilarasi V; Valson AT; Gowri M; Kabeerdoss J; Danda D
Rheumatol Int; 2018 Feb; 38(2):203-209. PubMed ID: 28550399
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease.
Liu Y; Zhang Y; Bian W; Fu J; Sun X; Chen D; Chen J; Zhao X; Li Y; Zhang W; Li Z
Clin Rheumatol; 2020 Feb; 39(2):491-497. PubMed ID: 31848912
[TBL] [Abstract][Full Text] [Related]
6. Improved clinical outcomes of tocilizumab
Zongfei J; Lijuan Z; Ying S; Dongmei L; Sifan W; Xiufang K; Lingying M; Yun L; Lili M; Huiyong C; Lindi J
Ther Adv Chronic Dis; 2021; 12():20406223211028776. PubMed ID: 34262681
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial.
Yunyun F; Yu P; Panpan Z; Xia Z; Linyi P; Jiaxin Z; Li Z; Shangzhu Z; Jinjing L; Di W; Yamin L; Xiaowei L; Huadan X; Xuan Z; Xiaofeng Z; Fengchun Z; Yan Z; Wen Z
Rheumatology (Oxford); 2019 Jan; 58(1):52-60. PubMed ID: 30124952
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients.
An W; Wu Z; Li M; Yu H; Zhao X; Wang X; Wang Y; Wang Q; Duan W; Kong Y; Ma H; Ou X; You H; Liu Y; Li P; Duan T; Jia J
Orphanet J Rare Dis; 2022 Aug; 17(1):307. PubMed ID: 35927746
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis.
Omar D; Chen Y; Cong Y; Dong L
Rheumatology (Oxford); 2020 Apr; 59(4):718-726. PubMed ID: 31511884
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Effectiveness and Safety of Mycophenolate Mofetil and Cyclophosphamide in Lupus Nephritis: Evidence from a Real-World Study.
Zhang X; Huang H; Gao D; Zhao J; Ji L; Fan Y; Hao Y; Zhang Z
Rheumatol Ther; 2023 Oct; 10(5):1199-1213. PubMed ID: 37418122
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study.
Peng L; Lu H; Zhou J; Zhang P; Li J; Liu Z; Wu D; Zhang S; Yang Y; Bai W; Wang L; Fei Y; Zhang W; Zhao Y; Zeng X; Zhang F
Arthritis Res Ther; 2021 Apr; 23(1):102. PubMed ID: 33827676
[TBL] [Abstract][Full Text] [Related]
12. Clinical features of immunoglobulin G4-related disease with central nervous system involvement: an analysis of 15 cases.
Peng L; Zhang P; Zhang X; Li J; Zhao J; Liu J; Fei Y; Zhang W; Zhu Y; Zhao Y; Zeng X
Clin Exp Rheumatol; 2020; 38(4):626-632. PubMed ID: 32083541
[TBL] [Abstract][Full Text] [Related]
13. Severe asthma as the initial clinical manifestation of IgG4-related disease: a retrospective clinical study.
Liu X; Shao C; Yu C; Huang H; Pan R; Xu K; Zhang X; Xu Z
BMC Pulm Med; 2022 Apr; 22(1):141. PubMed ID: 35413899
[TBL] [Abstract][Full Text] [Related]
14. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A
BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids in the treatment of IgG4-related disease-Prospects for new international treatment guidelines.
Yoshifuji H; Umehara H
Mod Rheumatol; 2023 Mar; 33(2):252-257. PubMed ID: 35993488
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and relapse risks factors of IgG4 related disease: a single-center retrospective study.
Zhang X; Zeng Z; Tian H; Wang N; Wang Y; Tong J; Chang B; Jin X; Huang D; Wang Y; Cui H; Guan L; Li Y
Clin Exp Med; 2023 Nov; 23(7):3527-3538. PubMed ID: 37392248
[TBL] [Abstract][Full Text] [Related]
17. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients.
Campochiaro C; Ramirez GA; Bozzolo EP; Lanzillotta M; Berti A; Baldissera E; Dagna L; Praderio L; Scotti R; Tresoldi M; Roveri L; Mariani A; Balzano G; Castoldi R; Doglioni C; Sabbadini MG; Della-Torre E
Scand J Rheumatol; 2016; 45(2):135-45. PubMed ID: 26398142
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids.
Yunyun F; Yu C; Panpan Z; Hua C; Di W; Lidan Z; Linyi P; Li W; Qingjun W; Xuan Z; Yan Z; Xiaofeng Z; Fengchun Z; Wen Z
Sci Rep; 2017 Jul; 7(1):6195. PubMed ID: 28733656
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review.
Wang Y; Li K; Gao D; Luo G; Zhao Y; Wang X; Zhang J; Jin J; Zhao Z; Yang C; Zhu J; Zhang J; Huang F
Intern Med J; 2017 Jun; 47(6):680-689. PubMed ID: 28321964
[TBL] [Abstract][Full Text] [Related]
20. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.
Majumder S; Mohapatra S; Lennon RJ; Piovezani Ramos G; Postier N; Gleeson FC; Levy MJ; Pearson RK; Petersen BT; Vege SS; Chari ST; Topazian MD; Witzig TE
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1947-1953. PubMed ID: 29526692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
